Amicus Therapeutics (FOLD) स्टॉक

Amicus Therapeutics (ticker FOLD) is a biopharmaceutical company focused on treatments for rare genetic diseases, notably Fabry disease. Its oral pharmacological chaperone, migalastat (marketed as Galafold), is approved in multiple regions and underpins current commercial revenue, while Amicus advances a pipeline that includes gene therapy and next‑generation small‑molecule programmes. Investors should note the blend of commercial execution (market uptake, reimbursement) and ongoing clinical and regulatory risk from trials and filings. Biotech stocks can be volatile around trial readouts, approvals, or partnership news, and valuation often reflects pipeline potential as much as current sales. With a market capitalisation around $2.61bn, Amicus sits between commercial and growth‑stage biotech. This is general educational information, not personalised advice; values can rise and fall and returns are not guaranteed, so consider your risk tolerance and conduct further research before investing.